Exporter

EN
FR
Doxorubicin
Statut de médicament essentiel
Description générale
Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.
INN
Doxorubicin
Codes ATC
L01DB01 L01AA01
Type de médicament
Chemical agent
Historique des statuts LME
Ajouté en 2015 (TRS 994) pour Follicular lymphoma
Ajouté en 2015 (TRS 994) pour Hodgkin lymphoma
Ajouté en 2019 (TRS 1021) pour Plasma cell myeloma
Demande refusée en 2021 (TRS 1035) pour Rhabdomyosarcoma primary site
Wikipédia
Doxorubicin
DrugBank
Doxorubicin
Recommandations
Section
Cytotoxic medicines
  • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
  • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Indications
Diffuse large B-cell lymphomas Malignant neoplasms of breast Hodgkin lymphoma Kaposi sarcoma of unspecified primary site Follicular lymphoma Unspecified malignant neoplasms of ill-defined or unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia Other specified malignant neoplasms of breast Plasma cell myeloma Rhabdomyosarcoma primary site Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative